Interactions with Patient Organizations are a fundamental part of the activities that Jazz Pharmaceuticals undertakes. These interactions ensure that Jazz Pharmaceuticals understands the needs of patients and is able to obtain valuable information to allow the company to be truly patient-centric. Patient Organizations provide valuable insight to aid in the development and improvement of innovative treatments and practices. Jazz Pharmaceuticals fosters Patient Organization relationships based on mutual trust, respect and goals that reflect Jazz Pharmaceutical’s transparent and ethical behavioural standards.
Relationships between pharma companies and Patient Organisations are regulated through the EFPIA Code and national industry codes to enforce public disclosure of any support to, or collaboration with Patient Organizations. Jazz Pharmaceuticals is committed to following these guidelines to meet and maintain high standards of transparency and integrity between the pharma industry and Patient Organizations across Europe.
This document summarises the methodology used in preparing Jazz Pharmaceutical’s disclosure report on Transfers of Value to Patient Organizations, in accordance with article 24 of the EFPIA Code of Practice.
Patient Organization (PO): not-for-profit legal entity (including the umbrella organisation to which it belongs), mainly composed of patients and/or caregivers, that represents and/or supports the needs of patients and/or caregivers and whose business address, place of incorporation or primary place of operation is in Europe.
Transfer of Value (ToV): The provision of financial or non-financial/indirect support to Patient Organizations in the form of donations, grants or sponsorship (including in relation to events/meetings) or funding for contracted services provided over the reporting period.
The patient organization report for the Jazz will outline:
Jazz Pharmaceuticals has affiliates in the following countries:
ToVs made to Patient Organizations for all countries in which Jazz has a presence are included in a single regional report for Europe. If a specific country is not listed in the report this indicates that there were no ToVs to Patient Organizations in that country.
The reporting period covers a full calendar year, immediately preceding the year in which the report is made.
Disclosures must be made within 6 months after the end of the relevant Reporting Period on Jazz’s Member Company website according to the EFPIA code. The information disclosed must remain in the public domain for a minimum of 3 years after the time such information is first disclosed. The general deadline for disclosures is 30 June.
This page is for U.S. residents only. By clicking on this page, you confirm you are a U.S. resident.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.